Buprenorphine Hydrochloride — Class II drug recall D-0876-2026
Ongoing recall by Par Health USA, LLC, reported 2026-10-07, distributed nationwide. Crystallization
| Recall number | D-0876-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Par Health USA, LLC, Rochester, MI, United States |
| Recall initiated | 2026-09-08 |
| Classified | 2026-09-29 |
| Reported by FDA | 2026-10-07 |
| Distributed | Nationwide (US) |
| Quantity | 154,210 bottles |
| NDC | 42023-0179, 42023-0179-05 |
| Lot numbers | 83912, 84234, 84990, 85003, 86443, 89909 |
| Expiration dates | 2026-10, 2026-11, 2026-12, 2027-01, 2027-05 |
Product
Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05
Reason for recall
Crystallization
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0876-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-10-13. Not affiliated with or endorsed by FDA. Not medical or legal advice.